A phase 2 trial of immunotherapy-based HMA combinations for patients with previously untreated MDS showed that there are unique cytogenic and molecular predictors of response.
In early study presented at the 66th American Society of Hematology Annual Meeting & Exposition, tagraxofusp demonstrated signs of clinical activity in patients with MDS…
Tislelizumab combined with irinotecan, paclitaxel, oxaliplatin, and 5-FU/leucovorin proved effective with manageable safety as frontline therapy for advanced HER2-negative, mismatch repairāproficient gastric and GEJ adenocarcinoma…
The median OS with frontline FOLFIRINOX was numerically lower than that seen with frontline NALIRIFOX in patients with metastatic PDAC.
NAPOLI 3 post hoc findings show dose reductions of liposomal irinotecan or oxaliplatin did not worsen OS in pancreatic ductal adenocarcinoma.
Obinutuzumab in combination with zanubrutinib showed favorable efficacy and manageable safety in elderly patients with untreated mantle cell lymphoma
Takeaways included updates from the CheckMate 816 study, advances in technology, the role of metabolites and mobile CT screening in predicting cancer risk, and the…
IĀ am pleased to begin a new series from City of HopeĀ®, one of the largest and most advanced cancer research and treatment organizations in the…
Key PointsInfrequent in CMML, AML-like mutations (CEBPA, FLT3, or NPM1) detect poor-prognosis CMML.
Distinct survival outcomes were found to correlate with VCK versus CK and the interplay between cytogenetic abnormalities and TP53 mutation status in patients with MDS
The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve the…
